Pulmonary Cell News 7.33 August 23, 2018 | |
| |
TOP STORYAn Extracellular Matrix Fragment Drives Epithelial Remodeling and Airway Hyperresponsiveness The authors showed that abrogation of leukotriene B4 (LTB4) signaling ameliorated inflammation and airway hyperresponsiveness (AHR) in a murine asthma model, yet global loss of LTA4H exacerbated AHR, despite the absence of LTB4. [Sci Transl Med] Full Article | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers investigated the effect of cigarette smoke on expression levels of CFLAR in bronchial biopsies from smokers and non-smokers and CFLAR transcript isoform-expression in a dataset of air-liquid interface-differentiated bronchial epithelial cells. [Sci Rep] Full Article Raman Micro-Spectroscopy for Accurate Identification of Primary Human Bronchial Epithelial Cells Scientists determined whether confocal Raman micro-spectroscopy shows sufficient sensitivity and specificity for identification of primary human bronchial epithelial cells to be used for live cell biological studies in vitro. [Sci Rep] Full Article Toll-Like Receptor Agonists Modulate Wound Regeneration in Airway Epithelial Cells Injured and not-injured bronchial epithelial cells were incubated with the toll-like receptor (TLR) agonists poly(I:C), lipopolisacharide, allergen Der p1, and supernatants from virus-infected epithelial cells, either alone or in combination with TLR inhibitors. Regeneration and immune response in injured and not-injured cells were studied. [Int J Mol Sci] Full Article LUNG CANCERScientists demonstrated that non-physiological levels of BCL11A in vitro and in vivo promote squamous-like phenotypes, while its knockdown abolishes xenograft tumor formation. [Nat Commun] Full Article | Press Release Investigators showed that the natural product rocaglamide enhanced natural killer (NK) cell-mediated lysis of non-small cell lung cancer cells in vitro and tumor regression in vivo. [Autophagy] Abstract Researchers showed that MAP17 expression is induced during lung tumorigenesis, particularly in lung adenocarcinomas, and provided in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumors, including cisplatin, carboplatin and EGFR inhibitors. [J Exp Clin Cancer Res] Full Article Kirsten rat sarcoma oncogene (KRAS) small interfering RNA (siRNA) and the epidermal growth factor receptor (EGFR) inhibitor significantly reduced the proliferation of A549 cells as well as KRAS and EGFR mRNA levels 24 hours after treatment. The results also indicated that the silencing of KRAS and EGFR has synergistic effects on the induction of apoptosis on the A549 cells. [J Cell Physiol] Abstract CASTOR1 Suppresses the Progression of Lung Adenocarcinoma and Predicts Poor Prognosis The authors report that the expression of CASTOR1 is significantly reduced in lung adenocarcinoma cell lines as compared with that in normal lung epithelial cells. [J Cell Biochem] Abstract Scientists showed that BENC-511 could significantly inhibit lung cancer cells invasion and metastasis both in vitro and in vivo. It not only inhibited PI3K/Akt signal pathway, but also directly suppressed phosphorylation of EGFR and nuclear translocation of β-catenin. [Chem Biol Interact] Abstract Subscribe to one of our other 19 science newsletters such as Intestinal Cell News & Human Immunology News. | |
| |
REVIEWSMicroRNA in Lung Cancer: Role, Mechanisms, Pathways and Therapeutic Relevance Recently, small ~20-24 nucleotides molecules called miRNAs have come into the limelight as they play outstanding role in the process of tumorigenesis by regulating cell cycle, metastasis, angiogenesis, metabolism and apoptosis. [Mol Aspects Med] Abstract Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
INDUSTRY NEWSBayer and Haplogen Collaborate to Develop New Treatments against Pulmonary Diseases Bayer and Haplogen GmbH have entered into a multi-year research collaboration agreement to identify new drug candidates for the treatment of pulmonary diseases such as COPD. [Bayer AG] Press Release Bristol-Myers Squibb Company announced that Opdivo received approval from the FDA as the first and only immuno-oncology treatment option for patients with metastatic small cell lung cancer whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy. [Bristol-Myers Squibb Company] Press Release Merck announced that the FDA has approved an expanded label for KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations, based on results of the KEYNOTE-189 trial. [Merck & Co., Inc.] Press Release Roche announced approval from the FDA for the cobas® epidermal growth factor receptor (EGFR) Mutation Test v2 as a companion diagnostic test with IRESSA®. [Roche Holding AG (PR Newswire Association LLC.)] Press Release Roche announced that the China National Drug Administration has granted marketing authorization for Alecensa® as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer. [Roche] Press Release | |
| |
POLICY NEWSThe National Institutes of Health (NIH) is investigating roughly a half-dozen research institutions based on suspicions that researchers with federal grants failed to disclose significant financial contributions from foreign governments. [STAT News] Editorial Trump Science-Adviser Pick Faces US Senate Committee Meteorologist Kelvin Droegemeier is in the hot seat, speaking before a US Senate committee during a hearing on his nomination to head the White House Office of Science and Technology Policy. [Nature News] Editorial Japanese Authorities Recommend Not Regulating Gene Editing A Japanese government panel announced that it recommends regulating only genetically modified organisms that have had foreign genes permanently introduced into their genomes and not those whose endogenous genes have been edited. This means that developers will not have to get approval from the government to produce gene-edited organisms. [The Scientist] Editorial
| |
EVENTSNEW Stem Cells & Organoids in Development & Disease Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Lung Diseases (German Research Center for Environmental Health) Postdoctoral Research Fellow – Respiratory Epithelial Cell Biology (STEMCELL Technologies Inc.) Postdoctoral Research Fellow – Respiratory Pharmacology (University of Exeter) Postdoctoral Position – Acute Lung Injury (University of Kentucky) Cancer Research Scholar – Lung Cancer (University of California) Postdoctoral Fellow – Non-Small Cell Lung Cancer (The University of Texas MD Anderson Cancer Center) Postdoctoral Fellow – Lung and Vascular Diseases (Icahn School of Medicine at Mount Sinai) Postdoctoral Fellow – Cellular Therapeutics in Chronic Lung Disease (Helmholtz Zentrum München) Principal Investigators – Cancer (University of Alabama Birmingham) Postdoctoral Fellow – Immunology (NYU Langone Health) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|